Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.
Identifieur interne : 000449 ( Ncbi/Merge ); précédent : 000448; suivant : 000450Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.
Auteurs : V. Mesnage [France] ; J L Houeto ; A M Bonnet ; I. Clavier ; I. Arnulf ; F. Cattelin ; G. Le Fur ; P. Damier ; M L Welter ; Yves AgidSource :
- Clinical neuropharmacology [ 0362-5664 ]
English descriptors
- KwdEn :
- Aged, Antipsychotic Agents (pharmacology), Antipsychotic Agents (therapeutic use), Cannabinoid Receptor Antagonists, Double-Blind Method, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Female, Humans, Levodopa, Male, Middle Aged, Movement Disorders (drug therapy), Movement Disorders (etiology), Neurotensin (antagonists & inhibitors), Parkinson Disease (complications), Parkinson Disease (drug therapy), Piperidines (pharmacology), Piperidines (therapeutic use), Pyrazoles (pharmacology), Pyrazoles (therapeutic use), Quinolines (pharmacology), Quinolines (therapeutic use), Receptors, Neurotensin (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Neurotensin, Receptors, Neurotensin.
- chemical , pharmacology : Antipsychotic Agents, Piperidines, Pyrazoles, Quinolines.
- chemical , therapeutic use : Antipsychotic Agents, Piperidines, Pyrazoles, Quinolines.
- complications : Parkinson Disease.
- drug therapy : Dyskinesia, Drug-Induced, Movement Disorders, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced, Movement Disorders.
- Aged, Cannabinoid Receptor Antagonists, Double-Blind Method, Female, Humans, Levodopa, Male, Middle Aged.
Abstract
The neuropeptides neurokinin B, neurotensin, and anandamide, the endogenous ligands of NK3, NT1, and CB1 receptors respectively, are known to interact with brain dopaminergic transmission. This study evaluated the effects of these three antagonists of the NK3 (SR 142801), neurotensin (SR 48692), and cannabinoid (SR 141716) receptors on the severity of motor symptoms and levodopa-induced dyskinesias after administration of a single dose of levodopa in 24 patients with Parkinson disease. In this exploratory randomized, double-blind, placebo-controlled study, at the dose used, the drugs tested were well tolerated and could not improve parkinsonian motor disability.
PubMed: 15190231
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001018
- to stream PubMed, to step Curation: 000F77
- to stream PubMed, to step Checkpoint: 000F77
Links to Exploration step
pubmed:15190231Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.</title><author><name sortKey="Mesnage, V" sort="Mesnage, V" uniqKey="Mesnage V" first="V" last="Mesnage">V. Mesnage</name><affiliation wicri:level="3"><nlm:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and Inserm, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre d'Investigation Clinique, Fédération de Neurologie and Inserm, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Houeto, J L" sort="Houeto, J L" uniqKey="Houeto J" first="J L" last="Houeto">J L Houeto</name></author><author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A M" last="Bonnet">A M Bonnet</name></author><author><name sortKey="Clavier, I" sort="Clavier, I" uniqKey="Clavier I" first="I" last="Clavier">I. Clavier</name></author><author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I" last="Arnulf">I. Arnulf</name></author><author><name sortKey="Cattelin, F" sort="Cattelin, F" uniqKey="Cattelin F" first="F" last="Cattelin">F. Cattelin</name></author><author><name sortKey="Le Fur, G" sort="Le Fur, G" uniqKey="Le Fur G" first="G" last="Le Fur">G. Le Fur</name></author><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name></author><author><name sortKey="Welter, M L" sort="Welter, M L" uniqKey="Welter M" first="M L" last="Welter">M L Welter</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name><affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2004 May-Jun</MedlineDate></PubDate></date><idno type="RBID">pubmed:15190231</idno><idno type="pmid">15190231</idno><idno type="wicri:Area/PubMed/Corpus">001018</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001018</idno><idno type="wicri:Area/PubMed/Curation">000F77</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F77</idno><idno type="wicri:Area/PubMed/Checkpoint">000F77</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F77</idno><idno type="wicri:Area/Ncbi/Merge">000449</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.</title><author><name sortKey="Mesnage, V" sort="Mesnage, V" uniqKey="Mesnage V" first="V" last="Mesnage">V. Mesnage</name><affiliation wicri:level="3"><nlm:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and Inserm, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre d'Investigation Clinique, Fédération de Neurologie and Inserm, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Houeto, J L" sort="Houeto, J L" uniqKey="Houeto J" first="J L" last="Houeto">J L Houeto</name></author><author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A M" last="Bonnet">A M Bonnet</name></author><author><name sortKey="Clavier, I" sort="Clavier, I" uniqKey="Clavier I" first="I" last="Clavier">I. Clavier</name></author><author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I" last="Arnulf">I. Arnulf</name></author><author><name sortKey="Cattelin, F" sort="Cattelin, F" uniqKey="Cattelin F" first="F" last="Cattelin">F. Cattelin</name></author><author><name sortKey="Le Fur, G" sort="Le Fur, G" uniqKey="Le Fur G" first="G" last="Le Fur">G. Le Fur</name></author><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name></author><author><name sortKey="Welter, M L" sort="Welter, M L" uniqKey="Welter M" first="M L" last="Welter">M L Welter</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name><affiliation></affiliation></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="ISSN">0362-5664</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antipsychotic Agents (pharmacology)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Cannabinoid Receptor Antagonists</term><term>Double-Blind Method</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Female</term><term>Humans</term><term>Levodopa</term><term>Male</term><term>Middle Aged</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Neurotensin (antagonists & inhibitors)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Piperidines (pharmacology)</term><term>Piperidines (therapeutic use)</term><term>Pyrazoles (pharmacology)</term><term>Pyrazoles (therapeutic use)</term><term>Quinolines (pharmacology)</term><term>Quinolines (therapeutic use)</term><term>Receptors, Neurotensin (antagonists & inhibitors)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neurotensin</term><term>Receptors, Neurotensin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antipsychotic Agents</term><term>Piperidines</term><term>Pyrazoles</term><term>Quinolines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Piperidines</term><term>Pyrazoles</term><term>Quinolines</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cannabinoid Receptor Antagonists</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Levodopa</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The neuropeptides neurokinin B, neurotensin, and anandamide, the endogenous ligands of NK3, NT1, and CB1 receptors respectively, are known to interact with brain dopaminergic transmission. This study evaluated the effects of these three antagonists of the NK3 (SR 142801), neurotensin (SR 48692), and cannabinoid (SR 141716) receptors on the severity of motor symptoms and levodopa-induced dyskinesias after administration of a single dose of levodopa in 24 patients with Parkinson disease. In this exploratory randomized, double-blind, placebo-controlled study, at the dose used, the drugs tested were well tolerated and could not improve parkinsonian motor disability.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15190231</PMID><DateCreated><Year>2004</Year><Month>06</Month><Day>10</Day></DateCreated><DateCompleted><Year>2004</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>3</Issue><PubDate><MedlineDate>2004 May-Jun</MedlineDate></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.</ArticleTitle><Pagination><MedlinePgn>108-10</MedlinePgn></Pagination><Abstract><AbstractText>The neuropeptides neurokinin B, neurotensin, and anandamide, the endogenous ligands of NK3, NT1, and CB1 receptors respectively, are known to interact with brain dopaminergic transmission. This study evaluated the effects of these three antagonists of the NK3 (SR 142801), neurotensin (SR 48692), and cannabinoid (SR 141716) receptors on the severity of motor symptoms and levodopa-induced dyskinesias after administration of a single dose of levodopa in 24 patients with Parkinson disease. In this exploratory randomized, double-blind, placebo-controlled study, at the dose used, the drugs tested were well tolerated and could not improve parkinsonian motor disability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mesnage</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and Inserm, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houeto</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Bonnet</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Clavier</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Arnulf</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Cattelin</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Le Fur</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Damier</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Welter</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Agid</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063387">Cannabinoid Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011804">Quinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018028">Receptors, Neurotensin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C091554">SR 142801</NameOfSubstance></Chemical><Chemical><RegistryNumber>146362-70-1</RegistryNumber><NameOfSubstance UI="C079087">SR 48692</NameOfSubstance></Chemical><Chemical><RegistryNumber>39379-15-2</RegistryNumber><NameOfSubstance UI="D009496">Neurotensin</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>RML78EN3XE</RegistryNumber><NameOfSubstance UI="C089032">rimonabant</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063387" MajorTopicYN="Y">Cannabinoid Receptor Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009496" MajorTopicYN="N">Neurotensin</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018028" MajorTopicYN="N">Receptors, Neurotensin</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15190231</ArticleId><ArticleId IdType="pii">00002826-200405000-00003</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I" last="Arnulf">I. Arnulf</name><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A M" last="Bonnet">A M Bonnet</name><name sortKey="Cattelin, F" sort="Cattelin, F" uniqKey="Cattelin F" first="F" last="Cattelin">F. Cattelin</name><name sortKey="Clavier, I" sort="Clavier, I" uniqKey="Clavier I" first="I" last="Clavier">I. Clavier</name><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name><name sortKey="Houeto, J L" sort="Houeto, J L" uniqKey="Houeto J" first="J L" last="Houeto">J L Houeto</name><name sortKey="Le Fur, G" sort="Le Fur, G" uniqKey="Le Fur G" first="G" last="Le Fur">G. Le Fur</name><name sortKey="Welter, M L" sort="Welter, M L" uniqKey="Welter M" first="M L" last="Welter">M L Welter</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Mesnage, V" sort="Mesnage, V" uniqKey="Mesnage V" first="V" last="Mesnage">V. Mesnage</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000449 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000449 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:15190231
|texte= Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:15190231" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |